3M Company
MMM has improved operations and credible FY26 momentum, but the stock at $165.89 already prices in much of that recovery while the quant target sits at $147.42, or -11.1% downside.
The stock is being priced like the recovery is both durable and still underappreciated. That is the wrong setup for new money. 3M has absolutely improved its operating cadence. Management raised FY26 sales, EPS, and free cash flow guidance after a strong Q2, and the language was unambiguous: "Given our strong first half performance, we're raising our guidance for the year for sales, EPS, and free cash flow." The company is now targeting adjusted EPS of $8.80-$8.95, organic growth above 3.5%, and free cash flow of $4.7B-$4.9B. Orders were up roughly 10%, backlog was up close to 20%, and the company has beaten EPS estimates in 8 straight quarters.
That is the bull case, and the market has already paid for it. At $165.89, the stock sits only 10.3% below its $184.90 52-week high and still trades on 29.31x trailing earnings, above the 26.0x peer average. Even on the stronger FY26 earnings base, the valuation only falls into the high-teens on forward EPS, which is fair, not cheap, for a company with a quality score of 54/100, risk score of 49/100, and financial health score of 31/100. The peer-multiple argument is also less comforting than it looks because the comp set has wide dispersion of 6.1x, so a peer-average anchor is noisy.
The key issue is that the underlying business is recovering from a weak base, not entering a step-change growth phase. FY2025 revenue fell 18.7% to $24.9B, EPS fell 159.5% to $6.04, and operating margin slipped to 19.5%. In Q2, EBITDA margin was only 17.2%, down 710 bps sequentially and 560 bps year over year, while tariffs and stranded costs created a $110M headwind. Consumer was down 2.1%, and management expects consumer electronics production down high teens in the back half. Those are not thesis-breakers, but they do cap how aggressive one should be with the multiple.
What the case depends on is simple. First, backlog must convert into sustained sales growth, not just one or two clean quarters. Second, second-half margin expansion of about 100 bps must show up despite tariffs and mix pressure. Third, the stronger free cash flow guide must prove that FY2025's $0.8B free cash flow was a trough and not a warning. Until that is demonstrated across a few more quarters, the stock looks more fully valued than underowned.
Quant call (SELL) diverges from analyst consensus (Hold: 2 buy / 2 hold / 2 sell) — resolve explicitly.
The most dangerous moment comes with victory.
Forward earnings power is clearly better than the FY2025 trough, with management now guiding to $8.80-$8.95 of FY26 adjusted EPS, which puts the stock at roughly 18.5x-18.9x that earnings base, more reasonable than the 29.31x trailing multiple but not obviously cheap for a company with only 54/100 quality and 31/100 financial health. The moat remains real in abrasives, safety, filtration, health-related consumables, and process know-how, but it looks more like a solid industrial franchise than a widening compounder over the next 3-5 years. AI is more an efficiency tool than a growth engine here, helping service, planning, and manufacturing productivity, while offering little reason to expand 3M's TAM materially. Regulation and tariffs still matter more than AI upside in the next year, and with consumer electronics expected down high teens, the path is improvement, not acceleration.
- Valuation is still full at 29.31x P/E versus 26.0x peers, while the quantitative price target is $147.42, implying -11.1% downside from $165.89.
- Execution has improved materially, with 8 straight EPS beats and FY26 guidance raised to $8.80-$8.95 EPS, >3.5% organic growth, and $4.7B-$4.9B free cash flow.
- Balance-sheet and cash-flow quality remain mixed, with debt/equity 4.25, debt/EBITDA 2.15, and FY2025 free cash flow only $0.8B despite an $85.6B market cap.
- Management raised FY26 guidance after Q2, now calling for adjusted EPS of $8.80-$8.95, organic sales growth greater than 3.5%, and free cash flow of $4.7B-$4.9B.
- Execution is measurably better, with 8 consecutive EPS beats, including $2.40 vs $2.25 in July 2026 and $2.14 vs $1.98 in April 2026.
- Demand visibility improved in Q2, with orders up about 10% and backlog up close to 20% exiting the quarter, supporting second-half volume.
- Industrial momentum is real, with SIBG +8.2% organic growth, $13M of June revenue from New Ulm bottleneck relief, and $700M cash received from the Madison Fire & Rescue JV close.
- The stock is not cheap for a restructuring story, trading at 29.31x P/E against a 26.0x peer average, while the peer set itself has wide dispersion of 6.1x, making multiple support less reliable.
- FY2025 reported fundamentals were weak, with revenue down 18.7% to $24.9B, EPS down 159.5% to $6.04, and operating margin slipping to 19.5% from 20.1%.
- Financial flexibility is still only average, with debt/equity 4.25, financial health score 31/100, and FY2025 free cash flow of just $0.8B.
- Some end markets remain soft, with Consumer -2.1% in Q2 on destocking and consumer electronics expected down high teens in the back half, while tariffs and stranded costs were a $110M Q2 headwind.
| Metric | Value | Context |
|---|---|---|
| Current price | $165.89 | Reference price for the $147.42 target, implying -11.1% downside |
| Price target | $147.42 | Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $24.9B | -18.7% YoY, a weak reported base |
| FY2025 EPS | $6.04 | -159.5% YoY, distorted but still a reminder of trough earnings volatility |
| FY2025 operating margin | 19.5% | Down from 20.1% in the prior year |
| Valuation | P/E 29.31x, P/S 3.45x, P/B 29.47x | P/E above peer average 26.0x, P/S roughly in line with peer 3.5x |
| FY26 guidance | Adj. EPS $8.80-$8.95, organic growth >3.5% | Raised after Q2 |
| FY26 free cash flow guide | $4.7B-$4.9B | With >100% free cash flow conversion expected |
| Leverage | Debt/Equity 4.25, Debt/EBITDA 2.15 | Balance sheet is manageable but not clean |
| FY2025 free cash flow | $0.8B | Very light relative to the equity value and below the FY26 run-rate goal |
| Q2 2026 operating indicators | Organic sales +5.4%, adj. operating margin 24.9%, EPS $2.40 | Orders up about 10%, backlog up close to 20% |
| 52-week position | Range $139.34-$184.90, now -10.3% vs high | Price is 3.2% above the 200-day average of $160.68 |
The biggest risk to the SELL call is that FY26 earnings power of $8.80-$8.95 and free cash flow of $4.7B-$4.9B prove durable enough for the market to keep paying nearly 29x earnings despite only moderate balance-sheet quality.
The next catalyst is Q3 earnings on October 20, 2026, where investors need to see backlog conversion, second-half margin expansion of about 100 bps, and confirmation that FY26 EPS can land within $8.80-$8.95.
3M posted a strong Q2 and raised FY26 guidance across sales, EPS, and free cash flow.
Given our strong first half performance, we're raising our guidance for the year for sales, EPS, and free cash flow.
We are raising our organic growth expectations from 3% to greater than 3.5% for the year.
EPS guidance is increasing from a range of $8.50-$8.70 to a range of $8.80-$8.95, or a growth of 9%-11% year-over-year.
We delivered strong performance in Q2, including organic growth of 5.4%, operating margin of 24.9%, up 40 basis points, earnings per share of $2.40, up 11%, and free cash flow of $1.3 billion with 107% conversion.
The updated guidance implies second-half organic sales growth of high threes or better over two times macro, and margin expansion of about 100 basis points from the prior year, resulting in EPS growth of approximately $0.30 at the midpoint.
MMM rates SELL, Medium conviction. The business is improving, and management is executing better than the market used to expect, but the stock at $165.89 already reflects much of that recovery while the quantitative target remains $147.42. This is not a call that 3M is broken. It is a call that the shares are too expensive for the growth, balance-sheet quality, and end-market mix still in front of them. A move to a more attractive entry point, or several more quarters that prove $8.80-$8.95 EPS and $4.7B-$4.9B free cash flow are durable, would be the main reasons to revisit the rating.
≣ Full research note tap to expand
Executive Summary
SELL, Medium conviction. Rated SELL, Medium conviction. 3M is executing better than it was a year ago, management raised FY26 guidance, and the beat streak is real, but the stock still trades at 29.31x earnings, above the 26.0x peer average, despite weak FY2025 reported earnings, thin FY2025 free cash flow of $0.8B, and a balance sheet that still screens stretched with 4.25x debt/equity. The setup is not broken operationally, it is simply too expensive relative to the forward improvement now embedded in the price.
Investment Thesis
The stock is being priced like the recovery is both durable and still underappreciated. That is the wrong setup for new money. 3M has absolutely improved its operating cadence. Management raised FY26 sales, EPS, and free cash flow guidance after a strong Q2, and the language was unambiguous: "Given our strong first half performance, we're raising our guidance for the year for sales, EPS, and free cash flow." The company is now targeting adjusted EPS of $8.80-$8.95, organic growth above 3.5%, and free cash flow of $4.7B-$4.9B. Orders were up roughly 10%, backlog was up close to 20%, and the company has beaten EPS estimates in 8 straight quarters.
That is the bull case, and the market has already paid for it. At $165.89, the stock sits only 10.3% below its $184.90 52-week high and still trades on 29.31x trailing earnings, above the 26.0x peer average. Even on the stronger FY26 earnings base, the valuation only falls into the high-teens on forward EPS, which is fair, not cheap, for a company with a quality score of 54/100, risk score of 49/100, and financial health score of 31/100. The peer-multiple argument is also less comforting than it looks because the comp set has wide dispersion of 6.1x, so a peer-average anchor is noisy.
The key issue is that the underlying business is recovering from a weak base, not entering a step-change growth phase. FY2025 revenue fell 18.7% to $24.9B, EPS fell 159.5% to $6.04, and operating margin slipped to 19.5%. In Q2, EBITDA margin was only 17.2%, down 710 bps sequentially and 560 bps year over year, while tariffs and stranded costs created a $110M headwind. Consumer was down 2.1%, and management expects consumer electronics production down high teens in the back half. Those are not thesis-breakers, but they do cap how aggressive one should be with the multiple.
What the case depends on is simple. First, backlog must convert into sustained sales growth, not just one or two clean quarters. Second, second-half margin expansion of about 100 bps must show up despite tariffs and mix pressure. Third, the stronger free cash flow guide must prove that FY2025's $0.8B free cash flow was a trough and not a warning. Until that is demonstrated across a few more quarters, the stock looks more fully valued than underowned.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $165.89 | Reference price for the $147.42 target, implying -11.1% downside |
| Price target | $147.42 | Medium confidence, basis earnings_growth_blend |
| FY2025 revenue | $24.9B | -18.7% YoY, a weak reported base |
| FY2025 EPS | $6.04 | -159.5% YoY, distorted but still a reminder of trough earnings volatility |
| FY2025 operating margin | 19.5% | Down from 20.1% in the prior year |
| Valuation | P/E 29.31x, P/S 3.45x, P/B 29.47x | P/E above peer average 26.0x, P/S roughly in line with peer 3.5x |
| FY26 guidance | Adj. EPS $8.80-$8.95, organic growth >3.5% | Raised after Q2 |
| FY26 free cash flow guide | $4.7B-$4.9B | With >100% free cash flow conversion expected |
| Leverage | Debt/Equity 4.25, Debt/EBITDA 2.15 | Balance sheet is manageable but not clean |
| FY2025 free cash flow | $0.8B | Very light relative to the equity value and below the FY26 run-rate goal |
| Q2 2026 operating indicators | Organic sales +5.4%, adj. operating margin 24.9%, EPS $2.40 | Orders up about 10%, backlog up close to 20% |
| 52-week position | Range $139.34-$184.90, now -10.3% vs high | Price is 3.2% above the 200-day average of $160.68 |
Financial Strength
The balance sheet is serviceable, not a strength. Debt/EBITDA of 2.15 is manageable for an industrial, but debt/equity of 4.25 and a financial health score of 31/100 show limited room for mistakes. Cash generation is the swing factor: FY2025 free cash flow was only $0.8B, yet Q2 showed a much healthier trajectory with $1.3B of free cash flow, 107% conversion, and inventory improved by seven days year over year. If the company delivers the guided $4.7B-$4.9B in FY26 free cash flow, balance-sheet anxiety fades meaningfully, but until that cash is realized, the market is being asked to capitalize a forecast rather than a proven run rate.
Competitive Position
3M still has a real moat rooted in materials science, process know-how, embedded customer relationships, and a broad installed position across industrial, safety, and specialty applications. That moat is durable enough to support solid margins and steady share in fragmented niches, but it is not obviously widening. The weak point is innovation intensity, with an Innovation Investment score of 19/100, which matters because several end markets are maturing and AI does not create a new demand layer for 3M the way it does for software or semis. The company should remain relevant and profitable, but the competitive position today argues for resilience, not for a structurally higher growth multiple.
Management & Guidance
Management credibility has improved. The company has delivered 8 straight EPS beats, and the latest call backed the numbers with operational specifics rather than vague optimism. CFO Anurag Maheshwari said, "We are raising our organic growth expectations from 3% to greater than 3.5% for the year." He also said, "EPS guidance is increasing from a range of $8.50-$8.70 to a range of $8.80-$8.95, or a growth of 9%-11% year-over-year." That said, the guidance still needs proof against known offsets, including the $110M tariff and stranded-cost headwind in Q2 and weaker consumer electronics demand in the second half. The beat record earns management more benefit of the doubt than it had previously, but not enough to erase valuation discipline.
Bull Case
- Management raised FY26 guidance after Q2, now calling for adjusted EPS of $8.80-$8.95, organic sales growth greater than 3.5%, and free cash flow of $4.7B-$4.9B.
- Execution is measurably better, with 8 consecutive EPS beats, including $2.40 vs $2.25 in July 2026 and $2.14 vs $1.98 in April 2026.
- Demand visibility improved in Q2, with orders up about 10% and backlog up close to 20% exiting the quarter, supporting second-half volume.
- Industrial momentum is real, with SIBG +8.2% organic growth, $13M of June revenue from New Ulm bottleneck relief, and $700M cash received from the Madison Fire & Rescue JV close.
Bear Case
- The stock is not cheap for a restructuring story, trading at 29.31x P/E against a 26.0x peer average, while the peer set itself has wide dispersion of 6.1x, making multiple support less reliable.
- FY2025 reported fundamentals were weak, with revenue down 18.7% to $24.9B, EPS down 159.5% to $6.04, and operating margin slipping to 19.5% from 20.1%.
- Financial flexibility is still only average, with debt/equity 4.25, financial health score 31/100, and FY2025 free cash flow of just $0.8B.
- Some end markets remain soft, with Consumer -2.1% in Q2 on destocking and consumer electronics expected down high teens in the back half, while tariffs and stranded costs were a $110M Q2 headwind.
Valuation & Price Target
Engine price target $147.42 (-11.1% vs current), Medium confidence.
- P/E Multiple: $135.39 (28% weight)
- P/S Multiple: $169.22 (20% weight)
- Quality-adjusted: $171.2 (20% weight)
- DCF: $31.38 (5% weight)
The rating aligns with the quant baseline SELL. The reason is straightforward: the quantitative target is $147.42, or -11.1% below the current $165.89, and that downside persists even after crediting better execution, raised FY26 guidance, and 8 straight beats. Sell-side consensus sits at a split Hold with 2 buy / 2 hold / 2 sell, but that is low-signal here. The operational recovery is real, yet the stock already discounts much of it given 29.31x trailing earnings, a peer average of 26.0x, and a still-moderate risk profile of 49/100.
Risk Assessment
Risk score 49/100 (Moderate). The biggest risk to the SELL call is that FY26 earnings power of $8.80-$8.95 and free cash flow of $4.7B-$4.9B prove durable enough for the market to keep paying nearly 29x earnings despite only moderate balance-sheet quality.
The Bottom Line
MMM rates SELL, Medium conviction. The business is improving, and management is executing better than the market used to expect, but the stock at $165.89 already reflects much of that recovery while the quantitative target remains $147.42. This is not a call that 3M is broken. It is a call that the shares are too expensive for the growth, balance-sheet quality, and end-market mix still in front of them. A move to a more attractive entry point, or several more quarters that prove $8.80-$8.95 EPS and $4.7B-$4.9B free cash flow are durable, would be the main reasons to revisit the rating.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr